Idiopathic (Essential) Hypertension - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：60頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Idiopathic (Essential) Hypertension - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Idiopathic (Essential) Hypertension - Pipeline Review, H1 2014’, provides an overview of the Idiopathic (Essential) Hypertension’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Idiopathic (Essential) Hypertension
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Idiopathic (Essential) Hypertension and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Idiopathic (Essential) Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Idiopathic (Essential) Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Idiopathic (Essential) Hypertension - Pipeline Review, H1 2014’, provides an overview of the Idiopathic (Essential) Hypertension’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Idiopathic (Essential) Hypertension
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Idiopathic (Essential) Hypertension and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Idiopathic (Essential) Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Idiopathic (Essential) Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Idiopathic (Essential) Hypertension Overview 7
Therapeutics Development 8
Pipeline Products for Idiopathic (Essential) Hypertension - Overview 8
Pipeline Products for Idiopathic (Essential) Hypertension - Comparative Analysis 9
Idiopathic (Essential) Hypertension - Therapeutics under Development by Companies 10
Idiopathic (Essential) Hypertension - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Idiopathic (Essential) Hypertension - Products under Development by Companies 15
Idiopathic (Essential) Hypertension - Companies Involved in Therapeutics Development 16
Novartis AG 16
Actelion Ltd 17
Forest Laboratories, Inc. 18
Les Laboratoires Servier SAS 19
Bayer AG 20
XOMA Corporation 21
Ahn-Gook Pharmaceutical Co., Ltd. 22
PhaseBio Pharmaceuticals, Inc. 23
Lee's Pharmaceutical Holdings Limited 24
NanoForm Therapeutics Ltd. 25
Idiopathic (Essential) Hypertension - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
(AHU-377 + valsartan) - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
carvedilol - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
(amlodipine + perindopril) - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
(nebivolol + valsartan) - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
(perindopril arginine + amlodipine besylate) - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
(nifedipine + candesartan cilexetil) - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
rostafuroxin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ACT-280778 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
PB-1046 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
telmisartan - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
candesartan cilexetil - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Idiopathic (Essential) Hypertension - Recent Pipeline Updates 54
Idiopathic (Essential) Hypertension - Dormant Projects 57
Idiopathic (Essential) Hypertension - Product Development Milestones 58
Featured News & Press Releases 58
Jun 12, 2013: Lee’s Pharma Enrolls First Patient In Phase IIb Clinical Trial Of Rostafuroxin In Italy 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60
List of Tables
Number of Products under Development for Idiopathic (Essential) Hypertension, H1 2014 8
Number of Products under Development for Idiopathic (Essential) Hypertension - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Idiopathic (Essential) Hypertension - Pipeline by Novartis AG, H1 2014 16
Idiopathic (Essential) Hypertension - Pipeline by Actelion Ltd, H1 2014 17
Idiopathic (Essential) Hypertension - Pipeline by Forest Laboratories, Inc., H1 2014 18
Idiopathic (Essential) Hypertension - Pipeline by Les Laboratoires Servier SAS, H1 2014 19
Idiopathic (Essential) Hypertension - Pipeline by Bayer AG, H1 2014 20
Idiopathic (Essential) Hypertension - Pipeline by XOMA Corporation, H1 2014 21
Idiopathic (Essential) Hypertension - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2014 22
Idiopathic (Essential) Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2014 23
Idiopathic (Essential) Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2014 24
Idiopathic (Essential) Hypertension - Pipeline by NanoForm Therapeutics Ltd., H1 2014 25
Assessment by Monotherapy Products, H1 2014 26
Assessment by Combination Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 33
Number of Products by Stage and Route of Administration, H1 2014 35
Number of Products by Stage and Molecule Type, H1 2014 37
Idiopathic (Essential) Hypertension Therapeutics - Recent Pipeline Updates, H1 2014 54
Idiopathic (Essential) Hypertension - Dormant Projects, H1 2014 57
List of Figures
Number of Products under Development for Idiopathic (Essential) Hypertension, H1 2014 8
Number of Products under Development for Idiopathic (Essential) Hypertension - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 13
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 31
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 32
Number of Products by Top 10 Route of Administration, H1 2014 34
Number of Products by Stage and Top 10 Route of Administration, H1 2014 35
Number of Products by Top 10 Molecule Type, H1 2014 36
Number of Products by Stage and Top 10 Molecule Type, H1 2014 37
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Idiopathic (Essential) Hypertension Overview 7
Therapeutics Development 8
Pipeline Products for Idiopathic (Essential) Hypertension - Overview 8
Pipeline Products for Idiopathic (Essential) Hypertension - Comparative Analysis 9
Idiopathic (Essential) Hypertension - Therapeutics under Development by Companies 10
Idiopathic (Essential) Hypertension - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Idiopathic (Essential) Hypertension - Products under Development by Companies 15
Idiopathic (Essential) Hypertension - Companies Involved in Therapeutics Development 16
Novartis AG 16
Actelion Ltd 17
Forest Laboratories, Inc. 18
Les Laboratoires Servier SAS 19
Bayer AG 20
XOMA Corporation 21
Ahn-Gook Pharmaceutical Co., Ltd. 22
PhaseBio Pharmaceuticals, Inc. 23
Lee's Pharmaceutical Holdings Limited 24
NanoForm Therapeutics Ltd. 25
Idiopathic (Essential) Hypertension - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
(AHU-377 + valsartan) - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
carvedilol - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
(amlodipine + perindopril) - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
(nebivolol + valsartan) - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
(perindopril arginine + amlodipine besylate) - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
(nifedipine + candesartan cilexetil) - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
rostafuroxin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ACT-280778 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
PB-1046 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
telmisartan - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
candesartan cilexetil - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Idiopathic (Essential) Hypertension - Recent Pipeline Updates 54
Idiopathic (Essential) Hypertension - Dormant Projects 57
Idiopathic (Essential) Hypertension - Product Development Milestones 58
Featured News & Press Releases 58
Jun 12, 2013: Lee’s Pharma Enrolls First Patient In Phase IIb Clinical Trial Of Rostafuroxin In Italy 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60
List of Tables
Number of Products under Development for Idiopathic (Essential) Hypertension, H1 2014 8
Number of Products under Development for Idiopathic (Essential) Hypertension - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Idiopathic (Essential) Hypertension - Pipeline by Novartis AG, H1 2014 16
Idiopathic (Essential) Hypertension - Pipeline by Actelion Ltd, H1 2014 17
Idiopathic (Essential) Hypertension - Pipeline by Forest Laboratories, Inc., H1 2014 18
Idiopathic (Essential) Hypertension - Pipeline by Les Laboratoires Servier SAS, H1 2014 19
Idiopathic (Essential) Hypertension - Pipeline by Bayer AG, H1 2014 20
Idiopathic (Essential) Hypertension - Pipeline by XOMA Corporation, H1 2014 21
Idiopathic (Essential) Hypertension - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2014 22
Idiopathic (Essential) Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2014 23
Idiopathic (Essential) Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2014 24
Idiopathic (Essential) Hypertension - Pipeline by NanoForm Therapeutics Ltd., H1 2014 25
Assessment by Monotherapy Products, H1 2014 26
Assessment by Combination Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 33
Number of Products by Stage and Route of Administration, H1 2014 35
Number of Products by Stage and Molecule Type, H1 2014 37
Idiopathic (Essential) Hypertension Therapeutics - Recent Pipeline Updates, H1 2014 54
Idiopathic (Essential) Hypertension - Dormant Projects, H1 2014 57
List of Figures
Number of Products under Development for Idiopathic (Essential) Hypertension, H1 2014 8
Number of Products under Development for Idiopathic (Essential) Hypertension - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 13
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 31
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 32
Number of Products by Top 10 Route of Administration, H1 2014 34
Number of Products by Stage and Top 10 Route of Administration, H1 2014 35
Number of Products by Top 10 Molecule Type, H1 2014 36
Number of Products by Stage and Top 10 Molecule Type, H1 2014 37
